Company Analysis
Sign in

Rapport Therapeutics, Inc. (RAPP)

Nasdaq: RAPP · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2024
Full chart Alerts Compare
Grade5.3
◀ Past 4.4● Present 7.3▶ Future 4.3
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$111M-42.4%
Earnings per share$-2.86+24.3%
Operating cash flow-$87.5M-34.9%
Cash$52.6M-7.3%
Debtn/a
Shareholders’ equity$485M+58.7%
Shares, diluted38.9M+87.7%
Return on equity-23.0%
The recordfrom its filings
Filings in 2026108
Newest filingNov 4 · 10-Q
Annual reportMar 10, 2026
Quarterly reportNov 4, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$47.2M
Insider buys, 12 months$22.0M
Patents granted1
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Trailing twelve months to Sep 2026Net income -$150MCash from operations -$121Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
232425
As filed, in USD. Nothing here is a forecast.

News

Nov 4, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 4, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 30, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 30, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
Oct 30, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
Oct 30, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 29, 2026 · SEC EDGAR · Form 305B2
Form 305B2
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton RAPP · research, not advice